Laryngeal squamous cell carcinoma (L-SCC) accounts for almost 2% of all malignancies worldwide, and together with oropharyngeal squamous cell carcinoma (OP-SCC) is the most common cancer type arising in the head-and-neck (HN-)region. In the past two decades, epidemiological and biological studies demonstrated that human papillomavirus (HPV), especially HPV type 16 (HPV16), has an aetiological role in a subset of OP-SCC located mainly in proximity to the lymphoid tissues of Waldeyer\'s ring such as tonsils and base of the tongue. Human papillomavirus-driven OP-SCC exhibit presence of HPV DNA with high viral loads ([@bib29]; [@bib21]; [@bib19]), transcriptionally active virus ([@bib51]; [@bib52]; [@bib4]; [@bib27]), and frequently show high expression of p16^INK4a^ ([@bib34]; [@bib16]; [@bib35]; [@bib17]), a robust surrogate marker for HPV involvement in cervical cancer (CxCa). Importantly, patients with HPV-driven OP-SCC are characterised by better overall and disease-free survival ([@bib2]; [@bib21]; [@bib19]).

In laryngeal carcinogenesis, tobacco smoking and alcohol consumption are recognised as the major risk factors ([@bib31]). Human papillomavirus DNA prevalences ranging from 3 to 60% have been reported ([@bib33]; [@bib1]; [@bib14]; [@bib30]); however, consistent biological evidence for viral involvement in L-SCC is still lacking. Varying HPV DNA prevalence reported across different epidemiological studies can be attributed to geographical differences, inadequate separation of laryngeal carcinoma cases from other cancers of the HN-region, for example, the OP-SCC, differences in analytical sensitivity of HPV-genotyping methods applied and limited spectrum of HPV types analysed. Currently, of 51 mucosal HPV types known today for CxCa ([@bib3]), 12 are classified as carcinogenic or high-risk (HR)-HPV (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59), 8 as probably/possibly carcinogenic or (p)HR-HPV (HPV26, 53, 66, 67, 68, 70, 73 and 82) and 31 as types of low/undetermined carcinogenicity or LR-HPV ([@bib20]). Most of the studies analysed L-SCC samples for the presence of only the five HR-HPV types 16, 18, 45, 31 and 33 that are most frequent in CxCa (reviews ([@bib24]; [@bib49]) and references therein), with HPV16 predominating. Few case reports identified pHR-HPV73 and 82 DNA in L-SCC by direct sequencing technology ([@bib32]; [@bib43]). The LR-HPV6 and 11 have been reported more frequently especially in association with recurrent respiratory papillomatosis ([@bib48]; [@bib36]).

Human papillomavirus DNA alone is not sufficient to identify HPV-driven cancers as has become evident for OP-SCC ([@bib21]; [@bib19]). High-risk-HPV DNA has been found in benign and normal tissue of the larynx ([@bib11]; [@bib8]), supporting the idea that HPV DNA presence alone cannot demonstrate causality. The concept for causal involvement of mucosal HPV in the pathogenesis of SCC includes: (a) presence of at least one viral genome copy per tumour cell, (b) active transcription of the viral oncogenes E6 and E7 and (c) interaction of the viral oncoproteins with central cellular regulator proteins of cell cycle and apoptosis signalling ([@bib9]; [@bib37]; [@bib55]). Such systematic analysis for biological HPV involvement in L-SCC are still missing. Three studies addressing the question of HPV causality used a limited set of markers (HPV16 mRNA and p16 expression) and indicated the existence of a small fraction of laryngeal cancers with active HPV involvement ([@bib38]; [@bib6]; [@bib25]).

To clarify the biological role of HPV in laryngeal carcinogenesis, we systematically analysed formalin-fixed paraffin-embedded (FFPE) and available subset of deep-frozen tissues (DFTs) of 102 L-SCC patients for the presence of all currently defined 51 mucosal HPV types, viral load, HPV mRNA expression and expression of cell cycle proteins p16^INK4a^, pRb, cyclin D1 (CyD1) and p53, the cellular surrogate markers for HPV transformation. Applying this broad method spectrum on multiple patient biopsies, we provide biological evidence for causal involvement of HPV16 in a small fraction of L-SCC, and suggest a combination of markers to define HPV-driven L-SCC.

Materials and methods
=====================

Patients and tissue samples
---------------------------

This study was approved by the ethics committee of the Medical Faculty of the University of Heidelberg, study code 176/2002. A total of 102 L-SCC patients were enrolled. Patients were diagnosed with invasive L-SCC and treated at the ENT department of the University Hospital Heidelberg, Germany between 1990 and 2006. Patient\'s age ranged from 39 to 82, with a median of 59 years. An initial study inclusion criterion was the availability of at least one FFPE biopsy of a primary L-SCC tumour (P-TU). For 11 patients P-TU was not available, therefore tumour recurrence (TU-Rec) or L-SCC as a secondary carcinoma (2nd Ca) were included. For 34 patients multiple FFPE biopsies (range 2--11; mean 4, median 3 FFPE biopsies pro-patient) were analysed. Owing to potential technical challenge imposed by formalin fixation in FFPE biopsies, we also analysed concordant DFT P-TU biopsies available for 55 patients (one DFT biopsy pro-patient). In total, 209 (154 FFPE and 55 DFT) biopsies were analysed for 102 patients; 91 patients had P-TU, 9 TU-Rec and 2 2nd Ca L-SCC. Per biopsy, tumour histology was independently verified by two study pathologists (CF and BL). Per patient, clinical data were collected from clinical charts and pathological reports.

Tissue sectioning, DNA and RNA extraction
-----------------------------------------

To probe the reproducibility of HPV DNA findings, each of 154 FFPE biopsies was sectioned twice and 308 DNA extracts were prepared. Deep-frozen tissue biopsies were sectioned once resulting in 55 DNA extracts. In total, 363 DNA extracts (154 × 2 FFPE and 55 DFT) were analysed for 102 patients.

To prevent cross-contamination during sectioning, each biopsy (FFPE or DFT) was sectioned with a new blade, the sectioning area was cleaned with 70% ethanol and acetone, respectively, and gloves were changed accordingly. Each experimental step included necessary controls ([Supplementary Information](#sup1){ref-type="supplementary-material"}).

For nucleic-acid extractions, FFPE and DFT tissue ribbons were obtained according to the sandwich method, that is, the first and the last 4-*μ*m-sections were stained by haematoxylin and eosin (H&E) stain to verify the presence of tumour cells. The number of ribbons required for nucleic-acid extraction depended on the biopsy size. For FFPE, 2--8 × 5 *μ*m, and for DFT 2--8 × 16 *μ*m tissue ribbons were cut, and genomic DNA was prepared as described ([@bib15]; [@bib19]). All DNA extracts were stored at −20 °C until use. Each FFPE and/or DFT biopsy that yielded HPV DNA+ result was sectioned again to obtain tissue ribbons for RNA extraction. Total RNA was extracted as described ([@bib15]; [@bib19]). RNA samples were stored at −80 °C until use.

Human papilloma virus genotyping and measurement of HPV16 viral load
--------------------------------------------------------------------

For genotyping 10 *μ*l, and for HPV16 quantitative real-time PCR (qPCR) 1 *μ*l, of DNA were used.

For HPV genotyping, broad-spectrum GP5+/6+-PCR/multiplex HPV genotyping assay (BSGP5+/6+-PCR/MPG) combining the BSGP5+/6+-PCR, which homogeneously amplifies all 51 genital HPV types generating biotinylated amplimers of ∼150 bp from the L1 region and 208 bp amplicon of *β*-globin ([@bib42], [@bib41]), and a Multiplex HPV Genotyping assay with bead-based xMAP Luminex suspension array technology (Qiagen, Hilden, Germany) ([@bib39], [@bib42]) was used. An L-SCC case (including all biopsies from one patient) was considered valid if the *β*-globin and/or HPV DNA+ was identified at least once. Each HPV DNA invalid (HPV and *β*-globin DNA−) result was verified by retesting.

The qPCR assay targeting HPV16-specific sequences of the *E6* gene was developed to calculate HPV16 viral genome copy-number per cell. Primer sequences used for qPCR are available upon request (Schmitt *et al*, manuscript in preparation). Quantitative real-time PCR for *β*-globin was used to verify the DNA quality and to measure the amount of input DNA. As on average, each tumour specimen contained ∼50% of tumour cells, and in HPV-transformed cells at least one genome copy per cell is expected, 0.5 copies of HPV16 genome per cell were set as a cut-off to define samples with high (HPV16~high~, ⩾0.5 copies per cell) or low (HPV16~low,~ \<0.5 copies per cell) viral load ([@bib19]).

E6\*I mRNA reverse transcription--PCR
-------------------------------------

One microlitre extracted RNA was subjected to a one-step reverse transcription--PCR protocol with the QuantiTect Virus Kit (Qiagen, Hilden, Germany) using HPV type-specific primers to amplify cDNA across the E6\*I splice site, as described ([@bib15]). The biotinylated strands of the amplimers were detected by hybridisation with type- and splice site-specific oligonucleotide probes coupled to fluorescence-labelled Luminex beads (Luminex Corp., Austin, TX, USA). The E6\*I mRNA assays are available for 20 HR-/pHR-HPV types for which existence of splice sites was demonstrated (([@bib15]) and references therein), and applicable on both DFT and FFPE biopsies ([@bib15]; [@bib17]). For detection of LR-HPV11 mRNA, the assay with primers designed to amplify 77 bp amplicon of the full-length *HPV11 E6* gene, and an oligonucleotide probe for *HPV11 E6* full-length detection, was applied.

Immunohistochemical analysis on TMA
-----------------------------------

A tissue microarray (TMA) was constructed carrying the tissue cores obtained from FFPE biopsies of all 102 patients, and cores with normal oral mucosa (NOM) of a cancer-free patient as a staining control. Each L-SCC core was representative of the invasive tumour as assessed by H&E analysis from single sections. Tissue microarray slides were stained manually as described ([@bib15]; [@bib18]) and on DAKO autostainer (Glostrup, Denmark).Protein expressions were evaluated separately by four investigators (FXB, DHol, BL and GH). Evaluation involved semi-quantitative scoring of the staining intensity (0=no expression, 1 or 2=low intensity and 3=high intensity) and the percentage of stained tumour cells, as described ([@bib15]; [@bib18]). For the simplicity of evaluation, only two protein expression categories were applied, low and high, with cut-off guided by protein expression in NOM. For p16^INK4a^, pRb and CyD1, positivity in \>25% of the tumour cells with intensity ⩾2 was required to define high protein expression ([Table 1](#tbl1){ref-type="table"}). Evaluation of staining for p53 in association with HPV involvement was more complex. In HPV-driven carcinomas, p53 expression is initially upregulated by HPV E7 actions ([@bib28]), but HPV E6 counteracts this upregulation by targeting p53 for ubiquitin-mediated degradation ([@bib37]). However, wild-type p53 protein level can increase to immunohistochemical (IHC) detectable levels during, for example, cellular damage caused by HPV infection ([@bib22]; [@bib13]; [@bib44]). Therefore, we defined p53 expression as p53~high~ when p53 positivity was found in \>50% of tumour cells with intensity=2, or in \>25 of tumour cells with intensity=3.

Definition of HPV DNA+, HPV16~high~/HPV16~low~ and HPV-driven L-SCC
-------------------------------------------------------------------

An L-SCC case (including all biopsies from one patient) was considered HPV DNA+ if at least one DNA extract yielded HPV DNA+ result.

To define HPV16 viral load per patient, DNA extract prepared from the first FFPE section, DNA extract prepared from the second, consecutive FFPE section of the same biopsy and DNA extract prepared from the DFT section results were combined. An L-SCC case was considered of high viral load (HPV16~high~) if quantitative results were above cut-off (⩾0.5 copies per cell) in ⩾50% of findings.

Finally, based on CxCa and HPV-driven OP-SCC data ([@bib15]; [@bib19]) and data in this study, we defined combination of HPV DNA+, E6\*I mRNA+ and high p16/low pRb (p16~high~/pRb~low~) protein pattern in tumour cells as a critical parameter to define HPV-driven L-SCC. Detailed overview of HPV DNA, E6\*I mRNA and IHC results per biopsy and per patient is provided in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

Results
=======

Human papilloma virus DNA prevalence in L-SCC tissues
-----------------------------------------------------

In this hospital series, 102 patients were included with their clinical characteristics, as described ([Table 2](#tbl2){ref-type="table"}). Altogether, 363 DNA extracts (154 × 2 FFPE and 55 DFT) prepared from 209 tumour tissue samples (154 FFPE and 55 DFT) were analysed for the presence of all currently defined 51 mucosal HPV types.

At least one valid DNA sample (HPV and/or *β*-globin DNA+) was obtained from 80 of the 102 patients (78%) with FFPE tissues and from all of the 55 patients with additionally DFT biopsy available, including 12 patients with no valid FFPE-derived sample ([Figure 1](#fig1){ref-type="fig"}). Ten patients with FFPE biopsies only, were DNA invalid and excluded from the analysis. Of the 92 L-SCC patients with at least one valid DNA sample, 32 (35%) were HPV DNA+, with a single HPV type found in 29 (91%) and multiple types found in 3 (9%) cases ([Table 3](#tbl3){ref-type="table"}). Human papilloma virus DNA positivity in present L-SCC series did not significantly change over the sampling period, with 30% in the first half of cases collected until 1997 and 24% in the second half of cases collected thereafter.

HPV type 16 was the most prevalent type found in 22 out of 29 (76%) single, and in all 3 multiple-type positive cases. High-risk-/pHR-HPV types 45, 53 and 70 were identified as single sequences in one case each and HPV56 in two cases. Two L-SCC cases harboured LR-HPV type 11 and 42, respectively. The three cases with multiple HPV types harboured HPV16 together with HPV33 (two cases) and HPV45 (one case).

Of 23 patients with at least one HPV DNA+ FFPE-derived DNA sample, and a valid, second FFPE-derived DNA sample, the same HPV type was found in only 6 (26%) of the second DNA samples. Among 16 valid DNA sample pairs derived from FFPE/DFT tissue pairs with at least one HPV DNA+ sample, only 5 (31%) had concordantly positive DNA samples. In total, for only 10 (32%) of 31 patients with at least one HPV DNA+ sample, the DNA findings could be reproduced in a second DNA sample ([Table 3](#tbl3){ref-type="table"}, [Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

In viral load analysis, 13 of the 25 HPV16 DNA+ samples were HPV16 DNA−, 8 had viral loads \<0.5 copies per cell, 2 had viral loads \>0.5 copies per cell and for 2 HPV16 viral loads could not be calculated (non-quantifiable) because of *β*-globin negativity. Thus, of the 23 HPV16 DNA+ tumours analysable by qPCR, 2 (9%) were defined as HPV16~high~ and 21 (91%) as HPV16~low~ ([Table 3](#tbl3){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}).

Interestingly, both HPV16~high~ L-SCC cases had reproducible HPV DNA+ findings from the consecutive FFPE section and/or DFT biopsies ([Table 3](#tbl3){ref-type="table"}). However, only 5 out of 21 (24%) HPV16~low~ L-SCC cases had reproducible HPV DNA+ results supporting the HPV16~low~ findings.

HPV E6\*I mRNA expression in HPV DNA+ L-SCC
-------------------------------------------

E6\*I mRNA was found in 6 out of 30 (20%) RNA analysable cases; 5 of them were found harbouring single HPV16 and one HPV70 ([Table 3](#tbl3){ref-type="table"}). Among the five HPV16 RNA+ cases, viral load was high in two (40%) cases (18 and 6800 genome copies per cell, respectively) and low in three (60%) other cases (with 0.20, 0.0001 and non-quantifiable copies per cell, respectively, [Table 3](#tbl3){ref-type="table"}). Among all 18 RNA− cases analysable by HPV16 qPCR, viral load was low including 9 (45%) non-quantifiable HPV16 DNA+ samples. This difference was statistically significantly (*χ*^2^-test, *P*=0.005).

P16^INK4a^, pRb, CyD1 and p53 protein expression in L-SCC
---------------------------------------------------------

Expression levels of p16^INK4a^ and pRb proteins could be analysed for 75, and CyD1 and p53 for 65 and 69 patients, respectively.

High expression of p16^INK4a^ (p16~high~) was found in 4 out of 75 (5%) cases, 3 of them were HPV16 DNA+ and RNA+ and the one remaining case was HPV11 DNA+ but RNA−. Thus, three of the five RNA+ cases (60%) analysable by IHC were p16~high~, and this was statistically significantly different from HPV RNA− and HPV DNA− groups, where only one out of 21 (5%, *χ*^2^-test, *P*=0.002) and none of 47 (*χ*^2^-test, *P*\<0.0001) showed p16~high~. The specificity of p16~high~ for HPV RNA+ group was even higher for HPV16 RNA+ cases only, that is, when HPV70 RNA+ case was excluded (75% *vs* 60%, [Table 4](#tbl4){ref-type="table"}).

Low pRb expression (pRb~low~) was found in 33 out of 75 (44%) cases. Of the 5 HPV RNA+, IHC analysable cases, 3 (60%) were pRb~low~, compared with 8 out of 21 (38%) HPV RNA− and 22 out of 47 (47%) HPV DNA− cases with pRb~low~. However, this difference was not statistically significant (*χ*^2^-test, *P*=0.373).

Low CyD1 expression (CyD1~low~) was found in 33 out of 65 (51%) cases. Of the 5 RNA+ L-SCC, 2 (40%) were CyD1~low~, compared with 9 out of 21 (43%) HPV RNA− and 22 out of 37 (59%) HPV DNA− cases with CyD1~low~.

Low p53 expression (p53~low~) was found in 53 out of 69 (77%) cases. Low p53 expression did not differ significantly between HPV status groups with 4 out of 5 (80%) HPV RNA+, 14 out of 21 (67%) HPV RNA− and 33 out of 41 (80%) HPV DNA− cases.

The two cases non analysable for HPV RNA (HPV42 and one of the two HPV56 DNA+ cases) showed p16~low~, pRb~high~, CyD1~high~ and p53~low~ expressions, respectively.

The marker combination p16~high~/pRb~low~, indicative of viral transformation, was found in none of the 47 HPV DNA− or the 21 HPV RNA− tumours, but in 3 out of 5 (60%) of the HPV RNA+ tumours analysable by IHC (*χ*^2^-test *P*\<0.0001 each). This difference was even higher when only HPV16 RNA+ L-SCC were selected (75% *vs* 60%, [Table 4](#tbl4){ref-type="table"}). These three tumours with HPV16 RNA+ and p16~high~/pRb~low~ IHC pattern (hereafter referred as HPV-driven tumours) showed p53~low~ in each case, whereas CyD1~low~ and high HPV16 load were found in two cases, respectively. Please see [Figure 2](#fig2){ref-type="fig"} for the examples of IHC staining.

Clinical characteristics of L-SCC patients and histopathological tumour patterns according to the HPV status
------------------------------------------------------------------------------------------------------------

Patients with HPV DNA− (*N*=60), and with HPV DNA+ or RNA+ tumours defined as non-HPV driven (*N*=28) did not show statistically significant differences considering gender, tumour localisation, tumour status or size, development of lymph node/distant metastases, or TU-Rec/secondary tumour/any metastasis, or alcohol drinking and smoking habits ([Table 2](#tbl2){ref-type="table"}, *χ*^2^-test, *P*\>0.05). The differences in clinicopathological features among the 3 HPV-driven, compared with the 28 non-HPV-driven or 60 HPV DNA− patients could not be statistically assessed owing to the small sample numbers in HPV-driven group. Interestingly, the median age of the three HPV-driven patients was 8 years lower than of those in the non-HPV-driven group, and 10 years lower than in the HPV DNA− group.

Pathological review of the 102 cases revealed 98 (96%) keratinising and 4 (4%) non-keratinising tumours, of which 1 was HPV DNA− and 3 were HPV DNA+ (one HPV16 DNA+/RNA−, one HPV11 DNA+/RNA− and one HPV16-driven; ([Table 2](#tbl2){ref-type="table"}). These observations, also based on small numbers, do not indicate that HPV-driven laryngeal SCC are preferentially non-keratinising, as has been observed for the oropharynx ([@bib10]; [@bib5]).

Discussion
==========

The biological role of HPV in the pathogenesis of L-SCC as compared with OP-SCC has not been sufficiently defined. Many studies in CxCa and its precursors have established individual markers of HPV transformation ([@bib23]; [@bib50]; [@bib47]; [@bib40]), and recently marker combinations have been comprehensively analysed in CxCa as a basis for stringent definition of HPV-driven mucosal cancers ([@bib15]). Such marker combinations have also been useful in OP-SCC to discriminate HPV-driven from non-HPV-driven tumours with or without HPV DNA ([@bib45]; [@bib21]; [@bib19]; [@bib26]).

We thoroughly analysed both FFPE and fresh, frozen tumour biopsies of 102 L-SCC patients for HPV presence and markers of biological activity. Using a stringent definition, we considered L-SCC cases as HPV-driven only when a marker combination with HPV DNA+/RNA+/p16~high~/pRb~low~ was identified. Among the 73 cases with valid DNA, IHC and RNA (HPV DNA+ only) data, we identified only 3 (4%) fulfilling this definition, all 3 harbouring HPV16 as a single infection.

We did not consider the presence of viral transcripts *per se* as a sufficient marker for HPV transformation. In the cervix, HPV16 E6\*I transcripts are also abundantly expressed in infection without transformation ([@bib40]); therefore, it is a marker of biological activity but is not transformation specific. Further, HPV16 DNA+ oropharyngeal SCC with HPV16 E6\*I transcription have been identified that, however, did not display cellular transformation markers and also did not show the better survival typically associated with HPV-driven OP-SCC ([@bib19]). Upregulation of p16^INK4a^ and downregulation of pRb are well established and frequent cellular consequences of HPV transformation, and were added here for a stringent definition of HPV-driven tumours.

In this series, there was no case positive for two functional markers, and 12 cases were positive for one functional marker only (nine DNA+/pRb~low~, two DNA+/RNA+ and one DNA+/p16~high~). These data indicate a robust separation of truly HPV-driven L-SCC *vs* HPV DNA+ cases in which the additional markers did not support the classification as HPV-driven tumours.

Among the 29 cases lacking either valid DNA, RNA or IHC data, 2 were p16~high~/pRb~low~ (DNA invalid, [Supplementary Table 1](#sup1){ref-type="supplementary-material"}) and 1 was HPV16 RNA+ (IHC invalid), representing at maximum three more candidates for HPV-driven L-SCC cases in this series.

Reproducibility of HPV DNA+ and HPV16 viral load supported our stringent definition of HPV-driven L-SCC. Among cases with multiple valid tissue sections, only 29% of non-HPV-driven but two of the two HPV-driven cases had reproducible HPV DNA+ findings. Also, all non-HPV-driven HPV16 DNA+ tumours showed viral loads far below 0.5 genome copies per cell, whereas two of the three HPV-driven L-SCC showed high viral loads with 6800 and 18 HPV16 genome copies per cell. The low viral load in the third HPV-driven case remains unexplained.

Taken together, of the 102 L-SCC cases that at least had valid DNA or IHC data, a minimum of 3 (3%) with potentially a maximum of 6 (6%) appear to be HPV driven. This small fraction of HPV-driven tumours in L-SCC is in line with three previous studies that demonstrated HPV16 DNA+/RNA+/p16~high~ in 2 of 27 (7% [@bib38]), 1 of 30 (3%) ([@bib25]) and in 3 of 60 (5%) L-SCC cases ([@bib6]). These data demonstrate that HPV16-driven L-SCC do exist but contribute only little to the overall L-SCC burden.

Ascertainment of the HPV-driven tumours as laryngeal and exclusion of any potentially oropharyngeal origin is crucial. The three HPV-driven tumours were clinically classified as primary laryngeal tumours without clinical evidence of OP extension. They were surgically removed *in toto* allowing pathological analysis of the tumour borders. One of the HPV-driven supraglottic tumours had cartilage, and the second supraglottic tumour had respiratory epithelium evident on H&E slides. The third HPV-driven tumour was a big glottic tumour extending also into supraglottis and subglottis, but importantly, again with no border extending into hypopharynx or base of the tongue.

The overall HPV DNA prevalence in our study was 35%, with HPV16 being the predominant genotype. This is comparable with previous studies from Central Europe where overall HPV DNA prevalence in L-SCC collected mainly between 1990 and 2006 varied between 20 and 35% ([@bib36]; [@bib12]; [@bib30]). Although HPV DNA positivity in L-SCC tissue samples is substantial, our data demonstrate that in most (around 90%) of these cases HPV is not the driving force. This separates L-SCC from OP-SCC in Central Europe where HPV prevalences of 15--50% were reported ([@bib45]; [@bib46]; [@bib21]; [@bib19]), and HPV has an aetiological role in ∼45% of HPV DNA+ OP-SCC tumours ([@bib45]; [@bib21]; [@bib19]).

Human papilloma virus DNA positivity in non-HPV-driven tumour biopsies could at least theoretically originate from the cross-contamination in routine pathological tissue processing or from laboratory contaminations. The similar HPV DNA prevalence in DFT-derived samples that had not gone through routine pathological tissue processing, when compared with FFPE tissues, and utmost care we applied to avoid and to detect any laboratory contaminations, appear to argue against such contamination hypothesis. Human papilloma virus DNA positivity could also result from non-transforming infection in tumour or neighbouring tissue, or may represent depositions of material from oral HPV infection at other sites.

The relative fraction of HPV DNA+ OP-SCC or tonsillar cancers appears to have increased in the last decades in the United States and Europe ([@bib7]). In our L-SCC case series, HPV DNA positivity did not significantly change with tumour collection time, and all three HPV16-driven and the three potentially HPV-driven L-SCC in our series were among the first half of tumours to be collected.

The BSGP5+/6+-PCR/MPG assay identifies all currently defined 51 mucosal HPV types, which allowed us to address the question whether presence of other HPV types in L-SCC may have been overlooked in the past. Besides HPV16 in 25 cases, we detected 3 HR- (HPV33, 45 and 56), 2 pHR- (HPV53 and 70) and 2 LR-HPV (HPV11 and 42) types as single or co-sequences in 10 cases. Eight of these cases showed no other marker for an HPV-driven tumour. One HPV70 DNA+ case was HPV70 E6\*I mRNA+ but the p16~low~/pRb~high~/CyD1~high~ IHC pattern argued against a transforming role of HPV70. One HPV11 DNA+ case had a high p16^INK4a^ expression, but also pRb~high~/CyD1~high~ and HPV11 RNA was not detectable. These data indicate that mucosal HPV types other than HPV16 do not contribute significantly to L-SCC development. This is in accordance with the data from (Chernock *et al*, 2012) who detected 3 HPV16 RNA+/p16~high~ and 1 HPV31 RNA+/p16~high~ L-SCC among the 60 cases tested.

We performed IHC analyses for four protein markers that are targeted directly (pRb and p53) or indirectly (p16^INK4a^ and CyD1) by HPV in CxCa. The p16~high~/pRb~low~ IHC marker combination required for our definition of HPV-driven L-SCC showed a very high specificity of 100% compared with 93% in HPV-driven OP-SCC ([@bib18]) and 97% in CxCa ([@bib15]).

All three HPV-driven L-SCC were p16~high~, as p16~high~ *per se* was part of our definition of HPV-driven tumours. At contrary, only 1 of the 72 non-HPV-driven/HPV DNA− L-SCC was p16~high~. This low frequency of p16^INK4a^ upregulation agrees with previous data ([@bib54]) and separates non-HPV-driven laryngeal from non-HPV-driven OP-SCC in which p16^INK4a^ upregulation was found in up to 20% ([@bib19]) or in up to 14% in HPV DNA− OP-SCC ([@bib46]; [@bib16]; [@bib26]).

Low pRb expression, also being part of our definition of HPV-driven tumour, was observed in all HPV-driven L-SCC. Among 72 non-HPV-driven/HPV DNA− L-SCC, 42% were pRb~low~. This again separates non-HPV-driven laryngeal from non-HPV-driven OP-SCC, of which only 14% were pRb~low~ ([@bib19]).

Finally, p53~low~ and CyD1~low~ seem not to be reliable markers for HPV-driven L-SCC. Although sensitivity of p53 for HPV-driven L-SCC appears sufficient (all HPV-driven L-SCC were p53~low~), specificity was very low as 75% of non-HPV-driven/HPV DNA− L-SCC also demonstrated with p53~low~. Low CyD1 expression was observed in two of the three HPV-driven, but also in 50% of non-HPV-driven/HPV DNA− L-SCC. These findings are in agreement with CxCa and OP-SCC studies analysing these four IHC markers using the same staining protocols and evaluation criteria, which showed that CyD1~low~ and p53~low~ had the lowest sensitivities for HPV-driven tumours ([@bib15]; [@bib18]).

For IHC analyses FFPE biopsies are essential. However, the fixation process is known to negatively affect nucleic-acid integrity ([@bib53]). In our study, validity of DNA extracted from FFPE biopsies (78%) was significantly lower than when extracted from DFT biopsies (100%). Validity of RNA from FFPE biopsies (94%) and from DFT biopsies (100%) was not significantly different. DNA and RNA invalidity was strongly associated with collection period before the end of 1995. Nine of the 10 patients with invalid DNA and both patients with invalid RNA were from this period, which represents 39% of all patients. Factors contributing to the lower fraction of RNA- *vs* DNA-valid FFPE-derived samples could be: (a) longer BSGP5+/6+-PCR/MPG amplicon size (150 bp for HPV and 208 bp for *β*-globin DNA *vs* 65--75 bp for HPV and 81 bp for ubiquitin C cDNA) and (b) higher copy-numbers per cell of the HPV and ubiquitin C mRNA.

By using a combination of four viral and surrogate markers, our study provides a robust biological evidence for the existence of truly HPV-driven L-SCC. Despite the relatively large case series analysed here, the low frequency of these HPV-driven tumours did not allow to address the question whether like in OP-SCC also in L-SCC HPV-driven tumours differ significantly in biological and clinical characteristics, especially better response to treatment and better survival. These questions can only be addressed in considerably larger, multicentric, collaborative studies.
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![**Study flow chart.** Overall flow chart showing the grouping of L-SCC in relation to HPV DNA, viral load, E6\*I mRNA expression and immunohistochemical (IHC) protein pattern defining HPV involvement as extrapolated from CxCa and OP-SCC. HPV16~high~---high, HPV16~low~---low HPV16 viral load as determined by HPV16 qPCR. ^a^For two samples, HPV16 viral load could not be quantified because of *β*-globin negativity in qPCR. ^b^For two samples RNA was not analysable, that is, both HPV RNA and ubiquitin C RNA were negative. ^c^For 13 patient cases defined as HPV DNA−, ^d^one RNA− and ^e^one RNA+ were of insufficient quality/quantity for IHC analysis. Combination of p16~high~/pRb~low~ expression was found in 3 HPV DNA+/RNA+ tumours, but in none of the 23 HPV DNA+/RNA− or 47 HPV− tumours. This difference was statistically significant (*χ*^2^-test, *P*=0.002 and *P*\<.0001). These three tumours were defined as HPV-driven L-SCC.](bjc2013296f1){#fig1}

![**Examples of IHC staining for p16^INK4a^, pRb and p53 in CxCa, L-SCC and NOM, respectively.** HPV16-driven CxCa (FFPE section, (**A**) p16~high~, (**E**) pRb~low~, (**I**) p53~low~); HPV16-driven L-SCC (FFPE section, (**B**) p16~high~, (**F**) pRb~low~, (**J**) p53~low~); HPV DNA− L-SCC (FFPE core on TMA, (**C**) p16~low~, (**G**) pRb~high~, (**K**) p53~high~); and NOM FFPE core on TMA, (**D**) p16~normal~, (**H**) pRb~normal~, (**L**) p53~normal~.](bjc2013296f2){#fig2}

###### Cut-offs and criteria for evaluation of p16^INK4a^, pRb, cyclin D1 and p53 protein expression

                **Protein** **expression in NOM**   **Protein expression in L-SCC defined as protein**~**low**~   **Protein expression in L-SCC defined as protein**~high~****   **Antibody reference**                                                                              
  ------------ ----------------------------------- ------------------------------------------------------------- -------------------------------------------------------------- ------------------------ ----- -------- ----- --------------- ------ -------- ---- --------- ------- ------------
  p16^INK4a^                    5                                             Nu+Cyt                                                           ⩽2                                    Diffuse/focal        ≤25   Nu+Cyt   \<2   Diffuse/focal   \>25   Nu+Cyt   ⩾2   Diffuse   E6H4       MTM
  pRb                          25                                               Nu                                                             ⩽3                                       Diffuse           ⩽25     Nu     ⩽3    Diffuse/focal   \>25     Nu     ⩾2   Diffuse    1F8    Novocastra
  CyD1                         25                                             Nu+Cyt                                                           ⩽3                                       Diffuse           ≤25     Nu     ≤3    Diffuse/focal   \>25     Nu     ⩾2   Diffuse   DCS-6      DAKO
  p53                           5                                               Nu                                                             ⩽2                                    Diffuse/focal        ⩽25     Nu     ⩽3    Diffuse/focal   \>25     Nu     3    Diffuse   DO.7       DAKO
                                                                                                                                                                                                          ⩽50     Nu     ⩽2    Diffuse/focal   \>50     Nu     ≥2   Diffuse                

'Diffuse or continuous\' is protein expression pattern observed over the whole tumour, and 'focal\' is protein expression pattern observed only in one part of the tumour. Nuclear pRb and CyD1 were abundant in NOM and found in up to 25% of proliferating cells in the basal and parabasal layers with intensity 2 or 3. Staining of NOM for p16^INK4a^ and p53 was observed in up to 5% of proliferating cells and with low intensity 1 or 2.

###### Clinical characteristics of patients stratified by HPV status

                                  **All (*****N*****=102)**   **DNA valid (*****N*****=92)**[a](#t2-fn2){ref-type="fn"}   **HPV**^**−**^(***N*****=60)**   **non-HPV driven (*****N*****=28)**[b](#t2-fn3){ref-type="fn"}   **HPV driven (*****N*****=3)**[c](#t2-fn4){ref-type="fn"}
  ------------------------------- --------------------------- ----------------------------------------------------------- -------------------------------- ---------------------------------------------------------------- -----------------------------------------------------------
  **Gender**                                                                                                                                                                                                                
  Male                            91 (89)                     81 (88)                                                     55 (93)                          24 (86)                                                          2 (67)
  Female                          11 (11)                     11 (12)                                                     4 (7)                            4 (14)                                                           1 (33)
  **Age (years)**                                                                                                                                                                                                           
  Median                          59.0                        59.0                                                        59.0                             57.0                                                             49.0
  **Localisation**                                                                                                                                                                                                          
  Supraglottic                    35 (34)                     30 (33)                                                     19 (32)                          9 (32)                                                           2 (67)
  Glottic                         65 (64)                     60 (65)                                                     39 (65)                          19 (68)                                                          1 (33)
  Subglottic                      2 (2)                       2 (2)                                                       2 (3)                            0 (0)                                                            0 (0)
  **Tumour status**                                                                                                                                                                                                         
  Primary                         91 (89)                     81 (88)                                                     52 (88)                          23 (82)                                                          2 (67)
  Recurrence                      9 (9)                       9 (10)                                                      5 (8)                            4 (14)                                                           1 (33)
  ⩾2nd Ca                         2 (2)                       2 (2)                                                       2 (3)                            1 (4)                                                            0 (0)
  **Tumour size**                                                                                                                                                                                                           
  T1--T2                          38 (42)                     35 (44)                                                     22 (40)                          13 (52)                                                          1 (50)
  T3--T4                          52 (58)                     45 (56)                                                     33 (60)                          12 (48)                                                          1 (50)
  No data                         12                          12                                                          5                                3                                                                1
  **Lymph nodes**                                                                                                                                                                                                           
  N0                              64 (73)                     59 (75)                                                     46 (82)                          20 (80)                                                          2 (100)
  N1+                             24 (27)                     20 (25)                                                     10 (18)                          5 (20)                                                           0 (0)
  No data                         14                          13                                                          3                                3                                                                1
  **Distant metastases**                                                                                                                                                                                                    
  M0                              85 (99)                     77 (99)                                                     55 (100)                         24 (96)                                                          2 (100)
  M1                              1 (1)                       1 (1)                                                       0 (0)                            1 (3)                                                            0 (0)
  No data                         12                          14                                                          4                                3                                                                1
  **Histopathological pattern**                                                                                                                                                                                             
  Keratinising                    98 (96)                     88 (96)                                                     59 (98)                          26 (93)                                                          2 (67)
  Non-keratinising                4 (4)                       4 (4)                                                       1 (2)                            2 (7)                                                            1 (33)
  **Clinical stage**                                                                                                                                                                                                        
  I--III                          43 (53)                     38 (53)                                                     15 (29)                          14 (56)                                                          1 (50)
  IV                              38 (47)                     34 (47)                                                     36 (71)                          11 (44)                                                          1 (50)
  No data                         21                          20                                                          8                                3                                                                1
  **Follow-up event**                                                                                                                                                                                                       
  Rec                             16 (16)                     15 (16)                                                     6 (10)                           9 (32)                                                           0 (0)
  2nd Ca                          10 (10)                     9 (10)                                                      7 (12)                           1 (4)                                                            1 (33)
  Met                             17 (16)                     14 (15)                                                     12 (20)                          2 (7)                                                            0 (0)
  No event (censored)             59 (58)                     54 (59)                                                     35 (58)                          16 (57)                                                          2 (67)
  **Alcohol use**                                                                                                                                                                                                           
  Yes                             65 (79)                     57 (78)                                                     37 (77)                          18 (82)                                                          1 (50)
  No                              9 (11)                      9 (12)                                                      6 (12)                           2 (9)                                                            1 (50)
  Former                          8 (10)                      7 (10)                                                      5 (10)                           2 (9)                                                            0 (0)
  No data                         20                          19                                                          11                               6                                                                1
  **Tobacco use**                                                                                                                                                                                                           
  Yes                             76 (85)                     68 (85)                                                     45 (83)                          24 (92)                                                          2 (100)
  No                              5 (6)                       5 (6)                                                       5 (9)                            0 (0)                                                            0 (0)
  Former                          8 (9)                       7 (8)                                                       4 (7)                            2 (8)                                                            0 (0)
  No data                         13                          12                                                          5                                2                                                                1
  **No of biopsies analysed**                                                                                                                                                                                               
  FFPE                            154 (74)                    144 (72)                                                    118 (73)                         22 (71)                                                          3 (60)
  DFT                             55 (26)                     55 (28)                                                     44 (27)                          9 (29)                                                           2 (40)

Abbreviations: DFT=deep-frozen tissue; FFPE=formalin-fixed paraffin-embedded.

Number of patients with valid biopsies, that is, *β*-globin and/or HPV DNA-positive.

Number of patients with non-HPV-driven L-SCC (*N*=28). One patient (HPV16, 45 DNA+) was also HPV16 RNA+ however, expression of proteins could not been assessed owing to poor tissue quality for IHC analysis. Therefore that patient could not be grouped into ^b^ or ^c^.

The three HPV-driven L-SCC patients with HPV DNA+/RNA+/p16~high~/pRb~low~ pattern.

###### Molecular characteristics of HPV DNA+ L-SCC patients

  **Patient number**    **Tissue biopsy**   **HPV DNA**   **HPV16 DNA copies/cell**   **Final HPV DNA and VL**   **HPV RNA**   **p16**~**high**~   **pRb**~**low**~   **CyD1**~**low**~   **p53**~**low**~   **HPV-driven L-SCC**
  -------------------- ------------------- ------------- --------------------------- -------------------------- ------------- ------------------- ------------------ ------------------- ------------------ ----------------------
  1                          FFPE~1~            16                  6769                        16 H                 16               \+                  \+                 \+                  \+                   \+
                             FFPE~2~            16                 Invalid                                                                                                                                             
                               DFT              16                   227                                                                                                                                               
  2                          FFPE~1~            16                   15                         16 H                 16               \+                  \+                  −                  \+                   \+
                             FFPE~2~            16                   18                                                                                                                                                
                               DFT                                                                                                                                                                                     
  3                          FFPE~1~          Invalid              Invalid                      16 L                 16               \+                  \+                 \+                  \+                   \+
                             FFPE~2~          Invalid              Invalid                                                                                                                                             
                               DFT              16                 \<0.001                                                                                                                                             
  4                          FFPE~1~             −                                              16 L                  −                −                  \+                  −                  \+                   −
                             FFPE~2~            16                  0.07                                                                                                                                               
                               DFT              16                  0.004                                                                                                                                              
  5                          FFPE~1~          Invalid                 0                         16 L                  −                −                  −                  \+                  \+                   −
                             FFPE~2~            16                    0                                                                                                                                                
                               DFT              16                    0                                                                                                                                                
  6                          FFPE~1~            16                    0                         16 L                  −               NA                  NA                 NA                  NA                   −
                             FFPE~2~          Invalid                 0                                                                                                                                                
                               DFT              16                 \<0.001                                                                                                                                             
  7                          FFPE~1~            16                    0                         16 L                  −                −                  \+                  −                  \+                   −
                             FFPE~2~          Invalid                 0                                                                                                                                                
                               DFT              16                 \<0.001                                                                                                                                             
  8                          FFPE~1~            16                    0                         16 L                  −                −                  −                  \+                  \+                   −
                             FFPE~2~             −                                                                                                                                                                     
                               DFT               −                                                                                                                                                                     
  9                          FFPE~1~             −                                              16 L                  −                −                  −                  \+                  −                    −
                             FFPE~2~            16                    0                                                                                                                                                
                               DFT               −                                                                                                                                                                     
  10                         FFPE~1~            16                    0                         16 L                  −                −                  −                   −                  −                    −
                             FFPE~2~          Invalid                 0                                                                                                                                                
                               DFT               −                                                                                                                                                                     
  11                         FFPE~1~          Invalid                 0                         16 L                  −                −                  −                  \+                  −                    −
                             FFPE~2~             −                                                                                                                                                                     
                               DFT              16                 \<0.001                                                                                                                                             
  12                         FFPE~1~             −                                              16 L                  −                −                  \+                  −                  \+                   −
                             FFPE~2~             −                                                                                                                                                                     
                               DFT              16                    0                                                                                                                                                
  13                         FFPE~1~             −                                              16 L                 16                −                  −                   −                  −                    −
                             FFPE~2~             −                                                                                                                                                                     
                               DFT              16                    0                                                                                                                                                
  14                         FFPE~1~             −                                              16 L                  −                −                  \+                 \+                  \+                   −
                             FFPE~2~             −                                                                                                                                                                     
                               DFT              16                    0                                                                                                                                                
  15                         FFPE~1~            --                                              16 L                  −                −                  \+                  −                  \+                   −
                             FFPE~2~            --                                                                                                                                                                     
                               DFT              16                 \<0.001                                                                                                                                             
  16                         FFPE~1~            16                   NQ                         16 L                  −                −                  −                  \+                  \+                   −
                             FFPE~2~            16                 Invalid                                                                                                                                             
                               DFT                                                                                                                                                                                     
  17                         FFPE~1~            16                    0                         16 L                  −                −                  −                   −                  \+                   −
                             FFPE~2~            --                                                                                                                                                                     
                               DFT                                                                                                                                                                                     
  18                         FFPE~1~            16                    0                         16 L                  −                −                  −                   −                  \+                   −
                             FFPE~2~            --                                                                                                                                                                     
                               DFT                                                                                                                                                                                     
  19                         FFPE~1~            16                 \<0.001                      16 L                  −                −                  −                  \+                  \+                   −
                             FFPE~2~            16                    0                                                                                                                                                
                               DFT                                                                                                                                                                                     
  20                         FFPE~1~            16                    0                         16 L                  −                −                  −                   −                  −                    −
                             FFPE~2~            --                                                                                                                                                                     
                               DFT                                                                                                                                                                                     
  21                         FFPE~1~            16                    0                         16 L                  −                −                  \+                 \+                  \+                   −
                             FFPE~2~            --                                                                                                                                                                     
                               DFT                                                                                                                                                                                     
  22                         FFPE~1~            16                    0                         16 L                  −               NA                  NA                 NA                  NA                   −
                             FFPE~2~            --                                                                                                                                                                     
                               DFT                                                                                                                                                                                     
  23                         FFPE~1~           16 45                0.20                        16 L                 16               NA                  NA                 NA                  NA                   −
                             FFPE~2~            16                    0                                                                                                                                                
                               DFT                                                                                                                                                                                     
  24                         FFPE~1~           16 33                  0                         16 L                  −                −                  \+                 \+                  −                    −
                             FFPE~2~            --                                                                                                                                                                     
                               DFT                                                                                                                                                                                     
  25                         FFPE~1~            16                   NQ                       16 L, 33                −                −                  −                   −                  −                    −
                             FFPE~2~            33                                                                                                                                                                     
                               DFT                                                                                                                                                                                     
  26                         FFPE~1~            45                                               45                   −               NA                  NA                 NA                  NA                   −
                             FFPE~2~            --                                                                                                                                                                     
                               DFT                                                                                                                                                                                     
  27                         FFPE~1~            56                                               56                Invalid             −                  \+                  −                  \+                   −
                             FFPE~2~            56                                                                                                                                                                     
                               DFT              --                                                                                                                                                                     
  28                         FFPE~1~            56                                               56                   −                −                  −                   −                  \+                   −
                             FFPE~2~            --                                                                                                                                                                     
                               DFT              --                                                                                                                                                                     
  29                         FFPE~1~            53                                               53                   −                −                  −                   −                  −                    −
                             FFPE~2~            --                                                                                                                                                                     
                               DFT                                                                                                                                                                                     
  30                         FFPE~1~            70                                               70                  70                −                  −                   −                  \+                   −
                             FFPE~2~            70                                                                                                                                                                     
                               DFT                                                                                                                                                                                     
  31                         FFPE~1~            11                                               11                   −               \+                  −                   −                  \+                   −
                             FFPE~2~            --                                                                                                                                                                     
                               DFT                                                                                                                                                                                     
  32                         FFPE~1~            42                                               42                Invalid             −                  −                   −                  \+                   −
                             FFPE~2~          Invalid                                                                                                                                                                  
                               DFT              --                                                                                                                                                                     

Abbreviations: NQ=not quantifiable owing to *β*-globin-negative results in qPCR; NA=tested but not analysable; VL=viral load that can be high (H, ⩾0.5 copies per cell) or low (L, \<0.5 copies per cell); protein~high~=high protein expression; protein~low~=low protein expression (see algorithm in [Table 1](#tbl1){ref-type="table"}).

'--\' in HPV DNA column means HPV DNA-negative finding; invalid, HPV and *β*-globin DNA-negative, or HPV and ubiquitin C RNA-negative; 'empty field\' indicates not available (e.g. DFT biopsy) or not tested (e.g. non-HPV16+ samples were not analysed with HPV16 qPCR). HPV-driven L-SCC are defined by HPV DNA+/RNA+/p16~high~/pRb~low~ pattern in the tumour cells. For protein expression, '--\' in column means the expected protein expression for p16~high~, pRb~low~, CyD1~low~, and p53~low~ was not found, or '+\', was found, respectively. The 'Patient number\' in this table does not correspond to the 'Patient number\' in the [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

###### Cellular protein expression in L-SCC compared with OP-SCC and CxCa, in relation to HPV16 status

                       **L-SCC**~**HPV\ DNA−**~ (***N*****=35)**   **L-SCC**~**HPV16\ DNA+\ RNA−**~ (***N*****=18)**   **L-SCC**~**HPV16\ RNA+**~ (***N*****=4)**   **OP-SCC**~**HPV\ DNA−**~ (***N*****=93)**[a](#t4-fn2){ref-type="fn"}   **OP-SCC**~**HPV16\ DNA+\ RNA−**~ (***N*****=55)**[a](#t4-fn2){ref-type="fn"}   **OP-SCC**~**HPV16\ RNA+**~ (***N*****=40)**[a](#t4-fn2){ref-type="fn"}   **CxCa**~**HPV16\ RNA+**~ (***N*****=44)**[b](#t4-fn3){ref-type="fn"}
  -------------------- ------------------------------------------- --------------------------------------------------- -------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------------------- -----------------------------------------------------------------------
  **p16^INK4a^**                                                                                                                                                                                                                                                                                                                                                                                      
  High                 0                                           0                                                   3 (75)                                       \(14\)                                                                  \(21\)                                                                          \(80\)                                                                    \(98\)
  Low                  35 (100)                                    18 (100)                                            1 (25)                                       \(86\)                                                                  \(79\)                                                                          \(20\)                                                                    \(2\)
  **pRb**                                                                                                                                                                                                                                                                                                                                                                                             
  High                 19 (54)                                     11 (61)                                             1 (25)                                       \(89\)                                                                  \(82\)                                                                          \(15\)                                                                    \(5\)
  Low                  16 (46)                                     7 (39)                                              3 (75)                                       \(11\)                                                                  \(18\)                                                                          \(85\)                                                                    \(95\)
  **CyD1**                                                                                                                                                                                                                                                                                                                                                                                            
  High                 15 (43)                                     9 (50)                                              2 (50)                                       \(56\)                                                                  \(54\)                                                                          \(5\)                                                                     (21)[c](#t4-fn4){ref-type="fn"}
  Low                  20 (57)                                     9 (50)                                              2 (50)                                       \(44\)                                                                  \(46\)                                                                          \(95\)                                                                    (79)[c](#t4-fn4){ref-type="fn"}
  **p53**                                                                                                                                                                                                                                                                                                                                                                                             
  High                 8 (23)                                      6 (33)                                              1 (25)                                       \(49\)                                                                  \(62\)                                                                          \(15\)                                                                    \(39\)
  Low                  27 (77)                                     12 (67)                                             3 (75)                                       \(51\)                                                                  \(38\)                                                                          \(85\)                                                                    \(61\)
  p16~high~/pRb~low~   0                                           0                                                   3 (75)                                       \(5\)                                                                   \(8\)                                                                           \(80\)                                                                    \(95\)
  Other                35 (100)                                    18 (100)                                            1 (25)                                       \(95\)                                                                  \(92\)                                                                          \(20\)                                                                    \(5\)

This table includes only L-SCC with analysable IHC data for all four proteins (35 of 60 HPV DNA− and 22 of 25 HPV16 DNA+ L-SCC). Non-HPV16 DNA+ cases are not included for better direct comparison with HPV16 DNA+ OP-SCC and CxCa, respectively.

From [@bib18].

From [@bib15]. Importantly, the protein expression in [@bib18] and [@bib15] was assessed using the same antibody references and evaluation criteria.

IHC results for CyD1 of CxCa series published in [@bib15] are reported here for the first time. Only a small fraction, 14 of 44 HPV16 RNA+ CxCa, had enough tissue material for cyclin D1 analysis. Eleven of these 14 (79%) showed CyD1~low~ expression. Expression of all four proteins was similar across L-SCC~HPV\ DNA−~ and L-SCC~HPV16\ DNA+\ RNA−~ groups. Such similarity was also observed among OP-SCC~HPV\ DNA−~ and OP-SCC~HPV16\ DNA+\ RNA−~ groups ([@bib18]).
